Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eledon Pharmaceuticals, Inc. - Common Stock
(NQ:
ELDN
)
2.385
-0.055 (-2.25%)
Delayed Quote
Updated: 10:07 AM EDT, Oct 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eledon Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
October 05, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
September 22, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
September 09, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
September 03, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
June 25, 2026
From
Natera, Inc.
Via
Business Wire
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
June 22, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
June 08, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
June 04, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
May 20, 2026
Conference call and webcast to discuss results to be held on June 22, 2026 at 8 a.m. ET
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
March 19, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
March 16, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
March 10, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
March 04, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 05, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
January 23, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
January 08, 2026
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
December 01, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
November 18, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
November 14, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
November 11, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
November 06, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
November 05, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
October 17, 2025
Conference call and webcast to discuss results to be held on November 7, 2025 at 8:00 a.m. ET
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
September 24, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
August 29, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
August 14, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
August 06, 2025
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
